By Healthcare Dive Editorial Team
Published July 16, 2026
The 340B drug discount program, once a niche mechanism designed to support the nation’s most vulnerable healthcare safety nets, has become the epicenter of a high-stakes legislative and economic battle. As new data reveals a staggering surge in spending, federal regulators are intensifying efforts to curb the program’s rapid growth, setting the stage for a major showdown between hospital systems and pharmaceutical manufacturers.
Main Facts: The Current State of 340B
At its core, the 340B program—established by Congress in 1992—requires pharmaceutical manufacturers to provide outpatient drugs to "covered entities" at significant discounts. These entities include hospitals that serve a high volume of low-income or uninsured patients, as well as specialized clinics. By purchasing drugs at a discount and receiving full reimbursement from insurance providers, these facilities can pocket the "spread," which hospitals argue is essential for maintaining operations, funding charity care, and offsetting the rising costs of inflation.
However, the program is currently facing unprecedented scrutiny. Recent data confirms that spending under the 340B umbrella has ballooned by tens of billions of dollars. This growth has outpaced earlier projections, leading policymakers to question whether the program has drifted far from its original legislative intent. With more than 60,000 entities now participating—a 600% increase since the turn of the millennium—the program’s footprint has expanded to cover a significant, and perhaps unmanageable, portion of the American pharmaceutical market.
A Chronology of Expansion and Conflict
The trajectory of the 340B program is marked by a transition from a targeted safety-net initiative to a massive, multi-billion-dollar enterprise.
- 1992: The Veterans Health Care Act establishes the 340B program to help safety-net hospitals manage outpatient drug costs.
- 2000-2010: A period of steady growth as more clinics and hospitals qualify under evolving federal definitions.
- 2015-2020: The era of consolidation. Research indicates that the financial incentives provided by 340B began to influence hospital M&A strategies, leading to a surge in the acquisition of outpatient clinics to expand 340B eligibility.
- 2023-2024: Senator Bill Cassidy (R-La.) releases a scathing report highlighting the 600% increase in participation since 2000, calling for urgent reform.
- 2025: Attempts by the administration to shift toward a rebate-based payment model fail due to industry pushback.
- July 2026: Regulators announce a radical proposal to slash Medicare payments for 340B drugs by one-third, effective in 2027.
Supporting Data: Drivers of Growth
The surge in spending is not merely a function of patient volume; it is driven by a complex interplay of clinical trends, industry consolidation, and the rising cost of specialized medicine.
1. The Consolidation Effect
According to recent investigations, including those led by Sen. Cassidy’s office, the program incentivizes hospitals to acquire private, independent physician practices. By bringing these clinics into a hospital system, these facilities become eligible for 340B discounts on drugs that would have previously been purchased at market rates. This "programmatic expansion" has been identified by health economists as a primary driver of overall healthcare spending growth.
2. Shifting Clinical Paradigms
The Health Resources and Services Administration (HRSA) has pointed to a fundamental shift in how medicine is delivered. The migration of care from inpatient settings to outpatient clinics—where 340B rules apply—has naturally increased the volume of discounted drugs.
3. High-Cost Therapeutic Categories
Spending is heavily concentrated in high-cost categories. Oncology, immunology, and anti-obesity medications are the primary culprits behind the recent spike in expenditures. Last year’s top-purchased drugs under the program included:
- Keytruda: A blockbuster cancer immunotherapy.
- Biktarvy: A cornerstone of modern HIV therapy.
- Darzalex Faspro: A high-cost monoclonal antibody used in cancer treatment.
Official Responses and Regulatory Maneuvers
The federal response to this growth has been multifaceted and, at times, contentious. Regulators are caught between the desire to maintain the financial health of safety-net providers and the need to prevent the program from being exploited by large hospital systems for profit.
The Trump administration’s attempt to introduce a rebate-based pilot program was intended to curb potential fraud. The proposal would have moved away from the upfront discount model to a retrospective rebate model, allowing manufacturers more oversight. When this initiative was scrapped following significant pushback from the American Hospital Association (AHA) and other advocacy groups, regulators pivoted to a more aggressive fiscal approach.
The latest proposal, announced this month, suggests a 33% reduction in Medicare payments for 340B-acquired drugs starting in 2027. This move is designed to make the program "site-neutral," ensuring that the government is not paying a premium for drugs regardless of where they are administered.
"We are seeing a systemic expansion that was never intended by the 1992 legislation," one regulatory analyst noted. "The goal of these cuts is to restore the balance between fair pricing and sustainable healthcare delivery."
Implications for the Future of Healthcare
The proposed 2027 payment cuts represent a turning point for the healthcare industry. If implemented, the implications are likely to be severe and far-reaching.
Impact on Safety-Net Hospitals
Hospitals argue that these cuts will be catastrophic. For rural and inner-city facilities, the 340B "spread" often covers the cost of other essential services, such as emergency room staffing, pharmacy counseling, and social services. A one-third reduction in revenue could force some smaller, struggling facilities to cut services or, in the worst-case scenario, close their doors.
Pharmaceutical Industry Dynamics
Conversely, pharmaceutical manufacturers argue that the current 340B structure encourages hospitals to select more expensive drugs to maximize their reimbursement spread. They contend that the program has become a profit center rather than a charity-care mechanism. By reducing the payments, manufacturers hope to see a more "rationalized" market where clinical efficacy, rather than discount eligibility, drives drug selection.
The Legislative Outlook
The coming months will be defined by intense lobbying. Hospital associations are already mobilizing to challenge the 2027 proposal in court and on Capitol Hill, while conservative lawmakers continue to push for tighter restrictions on which entities qualify for participation.
The fundamental question remains: Can a program designed for the 1990s be updated for the high-cost, high-tech landscape of the 2020s? As the 2027 deadline approaches, the tension between maintaining the safety net and curbing runaway healthcare spending will only intensify, forcing a potential restructuring of the entire drug delivery ecosystem in the United States.
For patients, the outcome is critical. Whether the result is lower drug prices for the public or a reduction in available community care, the 340B reform debate will undoubtedly be the defining healthcare policy narrative of the year.
